Compare SHOO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | SYRE |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1993 | 2016 |
| Metric | SHOO | SYRE |
|---|---|---|
| Price | $43.77 | $33.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $41.00 | ★ $55.50 |
| AVG Volume (30 Days) | ★ 940.0K | 745.7K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $2,362,727,000.00 | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $11.62 | N/A |
| P/E Ratio | $55.85 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $19.05 | $10.91 |
| 52 Week High | $44.99 | $35.31 |
| Indicator | SHOO | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 70.06 |
| Support Level | $41.25 | $33.24 |
| Resistance Level | $44.99 | $35.31 |
| Average True Range (ATR) | 1.49 | 1.79 |
| MACD | -0.05 | 0.18 |
| Stochastic Oscillator | 76.59 | 81.89 |
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.